FDA To Develop Biosimilar Innovation Plan, Modernize Its Processes

In 2018, FDA will focus on making the process for developing and approving biosimilar drugs more efficient, modernizing its own internal processes and technologies, and developing a comprehensive plan to encourage development of healthy foods, the agency announced in its 2018 Strategic Policy Roadmap released on Thursday (Jan. 11). In the roadmap, the agency outlines its key priorities for 2018 -- many of which are already underway. “Our Roadmap is not intended to be a traditional strategic plan; and it...